Applied DNA Sciences, Inc. (APDN)
NASDAQ: APDN · IEX Real-Time Price · USD
4.370
-0.630 (-12.60%)
At close: Apr 26, 2024, 4:00 PM
4.330
-0.040 (-0.92%)
After-hours: Apr 26, 2024, 6:45 PM EDT
Applied DNA Sciences Revenue
Applied DNA Sciences had revenue of $9.00M in the twelve months ending December 31, 2023, down -53.31% year-over-year. Revenue in the quarter ending December 31, 2023 was $891.16K, a -83.07% decrease year-over-year. In the fiscal year ending September 30, 2023, Applied DNA Sciences had annual revenue of $13.37M, a decrease of -26.43%.
Revenue (ttm)
$9.00M
Revenue Growth
-53.31%
P/S Ratio
0.42
Revenue / Employee
$172,997
Employees
52
Market Cap
3.77M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2023 | 13.37M | -4.80M | -26.43% |
Sep 30, 2022 | 18.17M | 9.14M | 101.25% |
Sep 30, 2021 | 9.03M | 7.10M | 367.40% |
Sep 30, 2020 | 1.93M | -3.46M | -64.16% |
Sep 30, 2019 | 5.39M | 1.49M | 38.06% |
Sep 30, 2018 | 3.90M | -847.92K | -17.85% |
Sep 30, 2017 | 4.75M | 564.83K | 13.49% |
Sep 30, 2016 | 4.19M | -4.82M | -53.53% |
Sep 30, 2015 | 9.01M | 6.29M | 231.05% |
Sep 30, 2014 | 2.72M | 685.00K | 33.64% |
Sep 30, 2013 | 2.04M | 181.53K | 9.79% |
Sep 30, 2012 | 1.85M | 885.85K | 91.43% |
Sep 30, 2011 | 968.85K | 449.00K | 86.37% |
Sep 30, 2010 | 519.84K | 224.68K | 76.12% |
Sep 30, 2009 | 295.16K | -577.85K | -66.19% |
Sep 30, 2008 | 873.01K | 751.09K | 616.05% |
Sep 30, 2007 | 121.92K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAPDN News
- 2 days ago - Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program - Accesswire
- 4 days ago - Applied DNA Announces 1-For-20 Reverse Stock Split - Accesswire
- 5 weeks ago - Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start - Accesswire
- 6 weeks ago - Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress - Accesswire
- 2 months ago - Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results - Accesswire
- 2 months ago - Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024 - Accesswire
- 3 months ago - Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 3 months ago - Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Accesswire